ReviewCJC open2022
Arrhythmia Monitoring for Risk Stratification in Hypertrophic Cardiomyopathy.
Review in CJC open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Atrial electrical alterations with intact cardiac structure and contractile function in a mouse model of an HCM-linkedJournal of molecular and cellular cardiology plus · 2025Article
- The value of cardiac magnetic resonance delayed enhancement combined with tissue tracking in discriminating cardiac amyloidosis from hypertrophic cardiomyopathy.Frontiers in cardiovascular medicine · 2025Article
- Prolonged mHealth-Based Arrhythmia Monitoring in Patients With Hypertrophic Cardiomyopathy (HCM-PATCH): Protocol for a Single-Center Cohort Study.JMIR research protocols · 2023Article
- Article
- Magnetic Resonance Left Ventricle Mass-Index/Fibrosis: Long-Term Predictors for Ventricular Arrhythmia in Hypertrophic Cardiomyopathy-A Retrospective Registry.Journal of cardiovascular development and disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy, presenting significant clinical heterogeneity. Arrhythmia risk stratification and detection are critical components in the evaluation and management of all cases of HCM. The 2020 American Heart Association/American College of Cardiology HCM guidelines provide new recommendations for periodic 24-48-hour ambulatory electrocardiogram monitoring to screen for atrial and ventricular arrhythmias. A strategy of more frequent or prolonged monitoring would lead to earlier arrhythmia recognition and the potential for appropriate treatment. However, whether such a strategy in patients with HCM results in improved outcomes is not yet established. The available evidence, knowledge gaps, and potential merits of such an approach are reviewed. Cardiac implantable electronic devices provide an opportunity for early arrhythmia detection, with the potential to enable early management strategies in order to improve outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.